PGR and ductal breast carcinoma in situ: Retrospective evaluation of oestrogen receptors (ER) and progesterone receptors (PgR) in 732 patients from the original study showed that tamoxifen reduced subsequent breast cancer events by 51% for women with ER-positive DCIS.9